# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BTIG analyst Mark Massaro maintains DermTech (NASDAQ:DMTK) with a Buy and lowers the price target from $4 to $2.
Stephens & Co. analyst Mason Carrico maintains DermTech (NASDAQ:DMTK) with a Equal-Weight and lowers the price target fr...
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.
DermTech (NASDAQ:DMTK) reported quarterly losses of $(0.560) per share which beat the analyst consensus estimate of $(0.570) by...
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...